CD19 and acute lymphoblastic leukemia: The development of dual-targeted CAR-NK cells holds particular promise (72), as evidenced by recent reports of CD19/CD20 dual-targeted CAR-NK cells exhibiting enhanced cytotoxicity against ALL cells (73).